CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
68 hedge funds and large institutions have $72.3M invested in CASI Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 34 closing their positions.
4.58% less ownership
Funds ownership: 37.97% → 33.39% (-4.6%)
20% less funds holding
Funds holding: 85 → 68 (-17)
39% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 23
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 34
68% less capital inflows, than outflows
Capital inflows: $6.42M | Capital outflows: $20.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.17M |
| 2 |
Millennium Management
New York
|
+$1.73M |
| 3 |
E
Ergoteles
New York
|
+$505K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$376K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.75M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$3.6M |
| 3 |
Bridgeway Capital Management
Houston,
Texas
|
-$1.51M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.42M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$971K |
CASI Hedge Fund Activity: Q2 2021 in Review
68 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2021, worth a combined $72.3M — down 43% from $127M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of CASI and 17 opened new positions — a net loss of 17 holders — while 23 trimmed existing stakes and 14 added.
The largest buyer was Renaissance Technologies, adding an estimated $2.17M. The largest seller was BlackRock, cutting an estimated $4.75M.
- 68 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2021, down from 85 in Q1 2021.
- Funds reported $72.3M of CASI Pharmaceuticals stock for Q2 2021, down 43% quarter-over-quarter.
- 17 funds opened new CASI Pharmaceuticals positions in Q2 2021 and 34 closed out, a net change of -17 holders.
- The largest CASI Pharmaceuticals buyer in Q2 2021 was Renaissance Technologies, an estimated $2.17M added.
- The largest CASI Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $4.75M sold.
Based on aggregated 13F filings for Q2 2021.